Rhonda Farnum compensation by year
Theravance Biopharma Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $506,303 |
| Bonus | $0 |
| Stock awards | $701,250 |
| Option awards | $0 |
| Non-equity incentive | $169,263 |
| Pension and deferred compensation | $0 |
| All other | $7,376 |
| Total | $1,384,192 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Theravance Biopharma, Inc. DEF 14A filed April 28, 2026, accession 0001104659-26-050454, and prior-year filings.
How this page was built: the Theravance Biopharma, Inc. filed document, accession 0001104659-26-050454. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 75,000 | $1,403,250 | — |
| RSU | 23,437 | $438,506 | — |
| RSU | 21,094 | $394,669 | — |
| PSU | 6,250 | $116,938 | — |
| RSU | 2,642 | $49,432 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Theravance Biopharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-23 | Disposition to the issuer derivative | — | 150,000 | — | 0 |
| 2026-09-23 | Disposition to the issuer | — | 89,062 | — | 0 |
| 2026-09-23 | Disposition to the issuer | — | 124,414 | — | 89,062 |
| 2026-09-15 | Sale | 10b5-1 | 6,657 | $17.03 | 213,476 |
| 2026-09-15 | Sale | 10b5-1 | 3,329 | $17.03 | 223,461 |
| 2026-09-15 | Sale | 10b5-1 | 3,328 | $17.03 | 220,133 |
| 2026-08-20 | Tax withholding | — | 5,667 | $16.95 | 226,790 |
| 2026-06-15 | Sale | 10b5-1 | 3,329 | $16.39 | 242,442 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Theravance Biopharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Rick Winningham | Chief Executive Officer | $1,472,019 |
| Aine Miller | Senior Vice President, Development and Head of Ireland Office | $1,448,573 |
| Rhonda Farnum · this page | Chief Business Officer and Senior Vice President, Commercial & Medical Affairs | $1,384,192 |
Rhonda Farnum's compensation dossier, Theravance Biopharma
You have read Rhonda Farnum's totals and holdings. The dossier adds each equity grant Theravance Biopharma disclosed for Rhonda Farnum and Theravance Biopharma's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Theravance Biopharma compensation record
free company briefThis page is one person within Theravance Biopharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Theravance Biopharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Theravance Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.